Key to the metabolic flexibility of these anti-tumour T cells, was their ability to adapt, with the compensatory upregulation of alternative glutamine transporters such as SLC6A14, that was not seen on the tumour cells, allowing for superior anti-tumour T cell responses, while curtailing tumour cell growth [8]. This evidence concerns the gene SLC6A14 and neoplasm.